Adam Christopher Palmer

Adam Christopher Palmer

Auto-generated profile, based on publicly available information

Adam Christopher Palmer

The University of North Carolina at Chapel Hill Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2016 in Cancer Cell
Verified
Journal Article
Closed access
SGShom Goel
Shom Goel
QWQi Wang
Qi Wang
AWApril C. Watt
April C. Watt
STSara M. Tolaney
Sara M. Tolaney
DDDeborah A. Dillon
Deborah A. Dillon
JZJean J. Zhao
Jean J. Zhao

1 March 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DPDeborah Plana
Deborah Plana
APAdam C. Palmer
Adam C. Palmer
PSPeter K. Sorger
Peter K. Sorger
Combination therapies are superior to monotherapy for many cancers. This advantage was historically ascribed to the ability of combinations to address tumor heterogeneity, but synergistic interaction is now a common explanation as well as a design criterion for new combinations. We review evidence that independent drug action, described in 1961, explains the efficacy of many practice-changing combination therapies: it provides populations of patients with heterogeneous drug sensitivities multiple chances of benefit from at least one drug. Understanding response heterogeneity could reveal predictive or pharmacodynamic biomarkers for more precise use of existing drugs and realize the benefits of additivity or synergy. Significance: The model of independent drug action represents an effective means to predict the magnitude of benefit likely to be observed in new clinical trials for combination therapies. The “bet-hedging” strategy implicit in independent action suggests that individual patients often benefit from only a subset—sometimes one—of the drugs in a combination. Personalized, targeted combination therapy, consisting of agents likely to be active in a particular patient, will increase, perhaps substantially, the magnitude of therapeutic benefit. Precision approaches of this type will require a better understanding of variability in drug response and new biomarkers, which will entail preclinical research on diverse panels of cancer models rather than studying drug synergy in unusually sensitive models.

19 February 2013 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
APAdam C. Palmer
Adam C. Palmer
RKRoy Kishony
Roy Kishony

10 June 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAdam C. Palmer
Adam C. Palmer
ETErdal Toprak
Erdal Toprak
MBMichael Baym
Michael Baym
SKSeungsoo Kim
Seungsoo Kim
AVAdrian Veres
Adrian Veres
RKRoy Kishony
Roy Kishony
Predicting evolutionary paths to antibiotic resistance is key for understanding and controlling drug resistance. When considering a single final resistant genotype, epistatic contingencies among mutations restrict evolution to a small number of adaptive paths. Less attention has been given to multi-peak landscapes, and while specific peaks can be favoured, it is unknown whether and how early a commitment to final fate is made. Here we characterize a multi-peaked adaptive landscape for trimethoprim resistance by constructing all combinatorial alleles of seven resistance-conferring mutations in dihydrofolate reductase. We observe that epistatic interactions increase rather than decrease the accessibility of each peak; while they restrict the number of direct paths, they generate more indirect paths, where mutations are adaptively gained and later adaptively lost or changed. This enhanced accessibility allows evolution to proceed through many adaptive steps while delaying commitment to genotypic fate, hindering our ability to predict or control evolutionary outcomes.

1 July 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAdam C. Palmer
Adam C. Palmer
RKRoy Kishony
Roy Kishony
Overexpression of a drug’s molecular target often increases drug resistance, offering a pathway for adaptive evolution and a tool for target identification. It is unclear though why this phenomenon applies to some drugs but not others. Here we gradually overexpressed antibiotic targets in Escherichia coli and found that drug resistance can increase, remain unchanged, decrease or even change non-monotonically. Even a single target can produce opposing responses to its different inhibitors. We explain these contradicting effects with quantitative models of enzyme inhibition that account for fitness costs and the biochemical activity or inactivity of drug–enzyme complexes. Thus, target overexpression confers resistance or sensitivity as a predictable property of drug mechanism, explaining its variable presence in nature as a resistance mechanism. Though overexpression screens may fail at identifying unknown targets, overexpressing known or putative targets provides a systematic approach to distinguish between simple inhibition and complex mechanisms of drug action.